Search for: "Price v. United States Government et al"
Results 261 - 280
of 334
Sorted by Relevance
|
Sort by Date
21 Mar 2023, 1:09 pm
City of Los Angeles (Rony Shram, et al, Real Parties in Interest) (2023) ___ Cal.App.5th ___. [read post]
9 Jan 2009, 7:00 am
(IP Think Tank) IEEE patent scorecard for 2008 is out (Innovationpartners) (Peter Zura's 271 Patent Blog) Patent databases: 2008 in review (Patent Librarian's Notebook) New kind codes for republished PCT documents (Patent Librarian’s Notebook) The model changes at PatentFreedom; Matsushita is top troll target (IAM) Patent litigation, the ITC, and hardship in the chip industry (IP finance) Global - Copyright Public domain day 2009 (Creative Commons), (Michael Geist)… [read post]
28 Apr 2008, 11:00 am
: (Spicy IP), US: Who’s to blame for rising drug prices? [read post]
6 Jan 2011, 8:02 pm
Franklin Salazar, et al. [read post]
17 Jul 2020, 3:00 am
Resources Code, § 21000 et seq.) when the state is acting on its own behalf and exercising its discretion in deciding to pursue licensing for a hydroelectric dam project? [read post]
3 Dec 2009, 2:18 am
The Case against Consolidation United States antitrust law aims to eliminate transactions that threaten the competitive process. [read post]
5 Oct 2021, 8:21 am
(HERE).The Conference brought together some of the most important and influential thinkers about the fundamentals of law in general, and that of the United States in particular. [read post]
30 Apr 2016, 12:10 pm
Intermediate v. strict scrutiny standard: but that’s one of the principal disputes right now. [read post]
1 Dec 2017, 12:44 pm
Kern County Board of Supervisors, et al. [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram) –… [read post]
13 Jul 2021, 10:58 am
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution –… [read post]
20 Feb 2009, 5:00 am
(Spicy IP) Copyright in characters – III – Delhi High Court decision in Raja Pocket Books v Radha Pocket Books (Spicy IP) Kenya Anti-Counterfeit Bill 2008 passed (Afro-IP) Kenya’s new anti-counterfeit legislation discussion (Afro-IP) Kuwait Kuwait adopts international classes 42-45 (Kuwaitmark) Macedonia New Industrial Property Law (Class 46) Nigeria Court moves from Uyo to continue proceedings in New York in… [read post]
31 Aug 2011, 10:27 am
More focused arbitration – covering price-adjustment clauses – is common even in the largest private target bids. [read post]
17 Aug 2011, 2:32 pm
Daniel Shaviro, Man Who Lost too Much: Zarin v. [read post]
1 Nov 2019, 9:01 am
At stake here is whether the FCC should open a rulemaking to consider changes to program rules governing fiber construction. [read post]
24 Jan 2019, 2:36 pm
For instance, in SEC v. [read post]
12 Jan 2017, 7:01 am
Amgen Inc., et al., 15-1039 and Amgen Inc. v. [read post]
16 Mar 2013, 4:58 pm
On reflection: Dietemann v. [read post]
24 Oct 2018, 4:33 pm
John Reed Stark Most readers are undoubtedly familiar with the concept of “insider trading” – that is, the purchase or sale by company insiders of their personal holdings in company shares based on material non-public information. [read post]
